Group 1 - GSK and Ionis have achieved the primary endpoint in the Phase 3 clinical trial of Bepirovirsen for chronic hepatitis B, with plans to submit regulatory filings in Q1 2026 [1] - Merck's subcutaneous formulation of Pembrolizumab has received FDA approval for 2025, with a focus on transitioning patients from intravenous infusion to the new formulation in 2026 [1] - Guangsheng Pharmaceutical's innovative drug GST-HG141 has completed patient enrollment for Phase 3 clinical trials, while Alvotech and Teva's biosimilar Eylea (AVT06) is expected to launch in the U.S. in Q4 2026 [1]

Core Viewpoint - Fujian Guangshentang Pharmaceutical Co., Ltd. is in the process of responding to the second round of inquiry from the Shenzhen Stock Exchange regarding its application for a specific stock issuance, indicating ongoing regulatory scrutiny and the need for compliance with disclosure requirements [1][2]. Group 1 - The company received an inquiry letter from the Shenzhen Stock Exchange on February 6, 2026, regarding its application for a specific stock issuance [1]. - The company, along with relevant intermediaries, has conducted a thorough study and response to the inquiries listed in the letter, which will be disclosed in detail on the company's official information platform [1]. - The stock issuance is subject to approval from the Shenzhen Stock Exchange and the China Securities Regulatory Commission, with uncertainties regarding the approval timeline [2].

Group 1 - Seedance2.0 is expected to be a pivotal moment for AI in the film industry, particularly in the production of AI comics and short dramas, leading to significant cost reductions and efficiency improvements in content creation [2] - The release of Seedance2.0 has sparked widespread evaluation and discussion within the industry, showcasing impressive capabilities in multi-modal thinking and video generation from various input types [2] - The film and television sector saw a substantial increase, with the film industry index rising by 13.83%, significantly outperforming other sectors, driven by the excitement around AI applications [2] Group 2 - The innovative pharmaceutical sector is experiencing a resurgence, with notable stock price increases among companies such as Wanbangde and Guangshengtang, indicating renewed investor interest [3] - The National Medical Products Administration announced that by 2025, China's pharmaceutical industry will accelerate its internationalization, with cumulative overseas licensing transactions for innovative drugs expected to exceed $130 billion [3] - A strategic cooperation agreement between Shiyao Group and AstraZeneca could yield up to $18.5 billion, marking a significant milestone in the company's business development transactions [3] Group 3 - Emerging technologies remain a key focus for the market, with a recommendation to concentrate on sectors benefiting from AI applications and international expansion [4] - The recent volatility in the Chinese stock market is attributed to global financial tightening concerns and pre-holiday cautious sentiment, but there is optimism regarding the domestic economic outlook [4] - The semiconductor sales growth is projected to accelerate, with high demand for domestic chips and related industries expected to continue through 2026 [4][5]

AI应用主线热度扩散 昨日，市场焦点在AI应用主线。受Seedance视频模型火爆"出圈"的提振，"AI+影视"方向大幅领涨。以 申万二级行业划分，影视院线指数昨日收涨13.83%，涨幅远超其他行业，光线传媒、幸福蓝海、捷成 股份收获20%幅度涨停，华谊兄弟、华策影视等涨超10%。 张大伟 制图 机构观点 Seedance2.0发布或为AI影视的"奇点"时刻，有望在AI漫剧、AI短剧等短内容方面率先得到广泛应用， 进一步推动漫剧、短剧制作大幅降本提效和产能供给释放 ◎记者 费天元 2月10日，A股全天窄幅盘整，沪指日内振幅仅0.41%，为开年以来最低，同时市场量能也出现萎缩，显 示春节假期前资金面趋于平淡。 截至收盘，上证指数报4128.37点，涨0.13%；深证成指报14210.63点，涨0.02%；创业板指报3320.54 点，跌0.37%；科创综指报1802.46点，涨0.31%。沪深两市合计成交21055亿元，较前一日缩量1439亿 元。 机构：新兴科技仍是主线 从2月9日的太空光伏到昨日的AI应用，节前市场重回科技成长主线。在部分机构看来，当前，新兴科 技仍是驱动A股盈利复苏的主要动力，建议聚焦"A ...

Market Overview - The pharmaceutical and biotechnology index decreased by 2.71%, underperforming the Shanghai Composite Index by 1.44 percentage points [4] - The innovative drug index (BK1106) saw a slight increase of 0.11%, while the Hang Seng Healthcare Index (HSCICH) fell by 1.37% [4] - The Hong Kong innovative drug ETF (513120) also experienced a decline of 0.47% [4] Sector Performance - The overall pharmaceutical sector weakened, lagging behind the Shanghai Composite Index, but the innovative drug sector showed relative resilience [5] - Specific stocks like Guangshentang surged due to the completion of Phase III clinical trials for hepatitis B treatments, while Changshan Pharmaceutical faced significant declines due to credit risks and expected losses [5] - In the Hong Kong market, Gilead Sciences-B received substantial investment from GIC, boosting its stock price, while Kangfang Biologics saw a notable drop due to stricter FDA approval standards [5] New Drug Developments - Danno Pharmaceuticals submitted a second listing application to the Hong Kong Stock Exchange, indicating a more rational investment environment focused on clinical viability and cash flow health [6][7] - The company has seven products in development, with TNP-2198 being the most advanced, expected to be approved in China by 2026 [6] - Three innovative drugs were approved during the week, including a treatment for type 2 diabetes and a drug for moderate to severe ulcerative colitis [12][13] Clinical Trials - From January 31 to February 6, 101 clinical trial registrations were disclosed, with 34 being in Phase II or above [8] - Notable trials include those for treatments targeting conditions such as obstructive sleep apnea and systemic lupus erythematosus [10][11] Emerging Trends - The investment landscape for innovative drugs is shifting towards a focus on clinical outcomes and commercial viability rather than merely the number of drug candidates [7] - The demand for effective treatments for ulcerative colitis is rising, with a significant increase in patient numbers expected by 2031 [14][15]

Core Insights - The pharmaceutical and biotechnology sector experienced a decline, with the pharmaceutical index dropping by 2.71% from January 31 to February 6, underperforming the Shanghai Composite Index by 1.44 percentage points [4] - The innovative drug sector showed relative resilience, with the innovative drug index (BK1106) increasing by 0.11% during the same period [4] - The market is witnessing a shift in investment focus towards clinical viability and financial sustainability rather than just pipeline quantity and novelty [7] Market Performance - The pharmaceutical and biotechnology index fell by 2.71%, while the Hang Seng Healthcare Index decreased by 1.37% [4] - The innovative drug ETF in Hong Kong (513120) also saw a decline of 0.47% [4] - Notable stock movements included Guangsheng Tang, which surged by 29.83% due to positive clinical trial news, and Changshan Pharmaceutical, which faced a decline due to credit risks and expected losses [5] Clinical Trials and Approvals - A total of 101 clinical trial registrations were disclosed, with 34 trials in Phase II or above [8] - Three innovative drugs received approval, including a new oral drug for moderate to severe ulcerative colitis by Cloudtop New Medicine [12][14] - Johnson & Johnson is exploring an upgraded treatment regimen for inoperable stage III non-small cell lung cancer, aiming to enhance the standard treatment protocol [15] Investment Trends - The investment environment for innovative drugs is becoming more rational, focusing on clinical certainty, commercial viability, and cash flow health [7] - The overall pharmaceutical industry has seen a 3.28% increase since the beginning of 2026, outperforming the CSI 300 index, with significant growth in hospital services, offline pharmacies, and outsourced drug development [5] New Drug Developments - The approval of the new drug by Cloudtop New Medicine addresses a significant unmet need in the treatment of ulcerative colitis, with a growing patient population expected to reach approximately 1.5 million by 2031 [13] - The drug is designed to provide rapid efficacy and deep mucosal healing, which is crucial for improving patient quality of life [14]

补充法律意见书（六） 国浩律师（上海）事务所 关 于 福建广生堂药业股份有限公司 2025 年度向特定对象发行 A 股股票 之 国浩律师（上海）事务所 补充法律意见书（六） 释 义 除以下特别说明外，本补充法律意见书中相关术语、简称与其在《国浩律师 （上海）事务所关于福建广生堂药业股份有限公司 2025 年度向特定对象发行 A 股股票之律师工作报告》《国浩律师（上海）事务所关于福建广生堂药业股份有 限公司 2025 年度向特定对象发行 A 股股票之法律意见书》及相关补充法律意见 书中的含义相同。 上海市山西北路 99 号苏河湾中心 25-28 层 邮编：200085 25-28/F, Suhe Centre, No.99 North Shanxi Road, Shanghai 200085, China 电话/Tel: +86 21 5234 1668 传真/Fax: +86 21 5234 1670 网址/Website: http://www.grandall.com.cn 二〇二六年二月 | 释 | 义 | 2 | | --- | --- | --- | | 第一节 | | 声明事项 6 | | 第二节 ...

股票简称：广生堂 股票代码：300436 关于福建广生堂药业股份有限公司 申请向特定对象发行股票的 第二轮审核问询函的回复 保荐机构（主承销商） 中国（上海）自由贸易试验区浦明路 8 号 二〇二六年二月 0 关于福建广生堂药业股份有限公司申请向特定对象发行股票的第二轮审核问询函的回复 深圳证券交易所： 贵所于 2026 年 2 月 6 日签发的《关于福建广生堂药业股份有限公司申请向 特定对象发行股票的第二轮审核问询函》（审核函〔2026〕020012 号）（以下简 称"第二轮审核问询函"）已收悉。根据问询函的要求，福建广生堂药业股份有 限公司（以下简称"广生堂"、"公司"、"发行人"）会同保荐机构国联民生 证券承销保荐有限公司（以下简称"国联民生承销保荐"、"保荐机构"、"保 荐人"）、国浩律师（上海）事务所（以下简称"发行人律师"）、北京德皓国 际会计师事务所（特殊普通合伙）（以下简称"发行人会计师""会计师"）等 相关方，本着勤勉尽责、诚实守信的原则，就第二轮审核问询函所提问题逐项认 真讨论、核查与落实，并逐项进行了回复说明。现将相关问题回复如下，请予审 核。 说明： 一、如无特别说明，本回复报告中使用的 ...

关于福建广生堂药业股份有限公司 申请向特定对象发行股票的审核问询函 有关财务事项的说明 德皓函字[2026]00000020 号 北 京 德 皓 国 际 会 计 师 事 务 所 (特 殊 普 通 合 伙 ) Beijing Dehao International Certified Public Accountants (Limited Liability Partnership) 关于福建广生堂药业股份有限公司 申请向特定对象发行股票的审核问询函 有关财务事项的说明 目 录 页 次 一、 关于福建广生堂药业股份有限公司申请向特定对 象发行股票的审核问询函有关财务事项的说明 1-45 关 于 福 建 广 生 堂 药 业 股 份 有 限 公 司 申 请 向 特 定 对 象 发 行 股 票 的 审 核 问 询 函 有 关 财 务 事 项 的 说 明 德皓函字[2026]00000020号 深圳证券交易所： 由福建广生堂药业股份有限公司转来的深圳证券交易所《关于福建广生堂药业股份有限 公司申请向特定对象发行股票的第二轮审核问询函》（审核函〔2026〕020012 号，以下简称 问询函）奉悉。我们已对问询函中由会计师 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 福建广生堂药业股份有限公司（以下简称"公司"）于 2026 年 2 月 6 日收 到深圳证券交易所（以下简称"深交所"）出具的《关于福建广生堂药业股份有 限公司申请向特定对象发行股票的第二轮审核问询函》（审核函〔2026〕020012 号）（以下简称"问询函"）。 公司按照问询函的要求，会同相关中介机构对问询函所列问题进行了认真研 究和落实，对问询函进行了逐项回复和说明，并根据相关要求对问询函回复进行 披露，具体内容详见公司同日在巨潮资讯网（http://www.cninfo.com.cn）披露 的相关公告文件。 证券代码：300436 证券简称：广生堂 公告编号：2026005 福建广生堂药业股份有限公司 关于公司申请向特定对象发行股票的第二轮审核问询函 回复的提示性公告 1 公司本次向特定对象发行股票事项尚需通过深交所审核，并获得中国证券监 督管理委员会（以下简称"中国证监会"）同意注册后方可实施，最终能否通过 深交所审核并获得中国证监会作出同意注册的决定及其时间尚存在不确定性。公 司将根据该事项进展情况及时 ...